BG
DXCM icon

Bellevue Group’s DexCom DXCM Stock Holding History

Bellevue Group’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.5M Sell
788,766
-58,639
-7% -$4.08M 1.18% 29
2025
Q4 		$56.2M Buy
847,405
+61,287
+8% +$3.96M 1.07% 25
2025
Q3 		$52.9M Sell
786,118
-74,710
-9% -$5.91M 1.1% 24
2025
Q2 		$75.1M Sell
860,828
-203,280
-19% -$15.9M 1.66% 17
2025
Q1 		$72.7M Buy
1,064,108
+19,064
+2% +$1.56M 1.63% 17
2024
Q4 		$81.3M Buy
1,045,044
+28,006
+3% +$2.07M 1.56% 18
2024
Q3 		$68.2M Sell
1,017,038
-251,649
-20% -$20.7M 1.1% 26
2024
Q2 		$144M Buy
1,268,687
+47,490
+4% +$6M 2.34% 14
2024
Q1 		$169M Buy
1,221,197
+306,604
+34% +$38.5M 2.58% 9
2023
Q4 		$113M Buy
914,593
+228,860
+33% +$23.4M 1.74% 15
2023
Q3 		$64M Sell
685,733
-75,983
-10% -$8.57M 1.03% 26
2023
Q2 		$97.9M Buy
761,716
+6,637
+0.9% +$803K 1.4% 23
2023
Q1 		$87.7M Sell
755,079
-233,397
-24% -$26.1M 1.27% 22
2022
Q4 		$112M Buy
988,476
+128,016
+15% +$14.1M 1.49% 20
2022
Q3 		$69.3M Sell
860,460
-68,048
-7% -$5.76M 0.99% 34
2022
Q2 		$69.2M Sell
928,508
-11,092
-1% -$1.01M 0.98% 34
2022
Q1 		$120M Sell
939,600
-1,012
-0.1% -$111K 1.4% 19
2021
Q4 		$126M Sell
940,612
-114,744
-11% -$16.5M 1.3% 21
2021
Q3 		$144M Buy
1,055,356
+76,252
+8% +$9.62M 1.46% 16
2021
Q2 		$105M Buy
979,104
+114,332
+13% +$11M 1.02% 26
2021
Q1 		$77.7M Buy
864,772
+11,544
+1% +$1.08M 0.82% 41
2020
Q4 		$78.9M Buy
853,228
+366,408
+75% +$32.7M 0.9% 34
2020
Q3 		$50.2M Buy
486,820
+76,000
+18% +$7.94M 0.69% 44
2020
Q2 		$41.6M Buy
410,820
+5,508
+1% +$493K 0.59% 45
2020
Q1 		$27.3M Buy
405,312
+91,412
+29% +$5.69M 0.53% 50
2019
Q4 		$17.2M Sell
313,900
-361,648
-54% -$17.2M 0.27% 68
2019
Q3 		$25.2M Buy
675,548
+15,004
+2% +$583K 0.47% 49
2019
Q2 		$24.7M Buy
660,544
+135,960
+26% +$4.27M 0.42% 54
2019
Q1 		$15.6M Buy
524,584
+213,352
+69% +$7.5M 0.86% 38
2018
Q4 		$9.32M Buy
311,232
+24,644
+9% +$782K 0.61% 47
2018
Q3 		$10.2M Sell
286,588
-797,000
-74% -$24.7M 0.65% 50
2018
Q2 		$25.7M Sell
1,083,588
-341,972
-24% -$7.25M 2.19% 13
2018
Q1 		$26.4M Buy
1,425,560
+358,600
+34% +$5.3M 2.62% 10
2017
Q4 		$15.3M Buy
1,066,960
+886,960
+493% +$11.5M 1.6% 20
2017
Q3 		$2.2M Buy
180,000
+30,000
+20% +$530K 0.23% 79
2017
Q2 		$2.74M Buy
150,000
+5,600
+4% +$103K 0.32% 69
2017
Q1 		$3.06M Sell
144,400
-19,600
-12% -$383K 0.41% 64
2016
Q4 		$2.45M Buy
+164,000
New +$2.91M 0.5% 52
2016
Q2 		– Sell
-80,000
Closed -$1.36M – 127
2016
Q1 		$1.36M Buy
+80,000
New +$1.34M 0.25% 89

Other funds holding DXCM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group's DXCM Position: Q1 2026 in Review

Bellevue Group reduced its DexCom (DXCM) stake by 6.9% in Q1 2026, selling an estimated $4.08M and leaving 788,766 shares worth $49.5M. The position accounts for 1.18% of the portfolio, ranked #29.

Bellevue Group first reported a position in DXCM in Q1 2016 and has held it in 39 quarters since. The position peaked at $169M in Q1 2024. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Bellevue Group held 788,766 shares of DexCom worth $49.5M as of Q1 2026.
  • Bellevue Group sold 58,639 DexCom shares in Q1 2026, an estimated $4.08M.
  • DexCom made up 1.18% of Bellevue Group's portfolio in Q1 2026, its #29 holding.
  • Bellevue Group first reported a position in DexCom in Q1 2016 and has held it in 39 quarters since.
  • Bellevue Group's DexCom position peaked at $169M in Q1 2024.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.